In 2024, Belén Torres and a team from Spain reviewed six clinical trials from 2012–2022 involving overweight or obese adults. They studied how probiotics, like Bifidobacterium and Lactobacillus strains, affect body weight, BMI, and fat mass without dieting, using data from PubMed, Scopus, and Cochrane databases.

In 2025, Jiping Chen and Jiawei Yao from Shandong University and Guangdong Vocational Academy of Art reviewed how the ketogenic diet (KD)—low-carb, high-fat—helps manage metabolic syndrome (MetS), a mix of high blood pressure, high sugar, big waist, high triglycerides (TG), and low good cholesterol (HDL). They looked at how KD boosts ketone bodies like β-hydroxybutyrate (β-BHB) to burn fat, improve insulin use, fix lipid levels, and cut swelling.

In 2025, health experts from EatingWell reviewed studies on walking after eating. They looked at how even a short stroll, like 15-30 minutes, can help people with or without diabetes by preventing blood sugar spikes, easing digestion, and more. Research showed walking right after meals lowers glycemic response better than before, cutting blood sugar rises by 20-30% in some cases.

In 2025, Samuel J. Dicken and a team from University College London ran a trial with 55 adults. They split people into two groups: one ate minimally processed foods like overnight oats or homemade spaghetti Bolognese for eight weeks, then switched to ultra-processed foods like breakfast bars or ready meals after a break.

A mouse study presented at ENDO 2025 by University of Michigan researchers found that tirzepatide (marketed as Mounjaro/Zepbound) caused ~20% weight loss in obese mice and dramatically slowed breast tumor growth, linking fat loss directly to improved cancer outcomes.